Pharma and charities in the UK gave a lukewarm welcome to the formal launch of the revamped Cancer Drugs Fund, saying the new entity – controlled by the National Institute For Health and Clinical Excellence (NICE) – will not solve underlying problems of drug reimbursement which, in turn, restrict access to novel oncology therapies.
NHS England earlier in July issued new guidelines on how cancer drugs will be appraised and funded in the UK,...








